Stock PGEN PRECIGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Precigen, Inc.

Equities

PGEN

US74017N1054

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
1.42 USD +1.43% Intraday chart for Precigen, Inc. +1.43% +5.97%
04-24 Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy CI
03-25 North American Morning Briefing : Tech in Focus on -2- DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy
Precigen Shares Fall After Downgrade From JPMorgan
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
Precigen Q3 Net Loss Widens, Revenue Falls
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Insider Buy: Precigen
Insider Buy: Precigen
Precigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
Precigen Gets US FDA Grants Breakthrough Therapy Designation to PRGN-2012 for Recurrent Respiratory Papillomatosis Treatment
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerseâ„¢ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Precigen Unveils Positive Phase 1 Data From Advanced Stage Platinum Resistant Ovarian Cancer Patients
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers
Sector Update: Health Care Stocks Advancing Late Wednesday
Sector Update: Health Care Stocks Higher in Afternoon Trading
Sector Update: Health Care
Precigen Gets FDA Clearance for Phase 2 Study of Cervical Cancer Combination Treatment
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PGEN Stock
  4. News Precigen, Inc.
  5. Other languages